These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38243318)

  • 1. The genomic alterations in glioblastoma influence the levels of CSF metabolites.
    Wang DH; Fujita Y; Dono A; Rodriguez Armendariz AG; Shah M; Putluri N; Pichardo-Rojas PS; Patel CB; Zhu JJ; Huse JT; Parker Kerrigan BC; Lang FF; Esquenazi Y; Ballester LY
    Acta Neuropathol Commun; 2024 Jan; 12(1):13. PubMed ID: 38243318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors.
    Ballester LY; Lu G; Zorofchian S; Vantaku V; Putluri V; Yan Y; Arevalo O; Zhu P; Riascos RF; Sreekumar A; Esquenazi Y; Putluri N; Zhu JJ
    Acta Neuropathol Commun; 2018 Aug; 6(1):85. PubMed ID: 30170631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Metabolomic Analysis of IDH1
    Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
    Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.
    Martínez-Ricarte F; Mayor R; Martínez-Sáez E; Rubio-Pérez C; Pineda E; Cordero E; Cicuéndez M; Poca MA; López-Bigas N; Ramon Y Cajal S; Vieito M; Carles J; Tabernero J; Vivancos A; Gallego S; Graus F; Sahuquillo J; Seoane J
    Clin Cancer Res; 2018 Jun; 24(12):2812-2819. PubMed ID: 29615461
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
    Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
    Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GC/MS-based metabolomic analysis of cerebrospinal fluid (CSF) from glioma patients.
    Nakamizo S; Sasayama T; Shinohara M; Irino Y; Nishiumi S; Nishihara M; Tanaka H; Tanaka K; Mizukawa K; Itoh T; Taniguchi M; Hosoda K; Yoshida M; Kohmura E
    J Neurooncol; 2013 May; 113(1):65-74. PubMed ID: 23456655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations.
    Liu HQ; Li WX; An YW; Wu T; Jiang GY; Dong Y; Chen WX; Wang JC; Wang C; Song S
    Int J Immunopathol Pharmacol; 2022; 36():3946320221139262. PubMed ID: 36377597
    [No Abstract]   [Full Text] [Related]  

  • 12. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1
    Kondo N; Barth RF; Miyatake SI; Kawabata S; Suzuki M; Ono K; Lehman NL
    J Neurooncol; 2017 May; 133(1):107-118. PubMed ID: 28534152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of cerebrospinal fluid circulating tumor DNA in the diagnosis of gliomas.
    Zhao Z; Zhang C; Li M; Shen Y; Feng S; Liu J; Li F; Hou L; Chen Z; Jiang J; Ma X; Chen L; Yu X
    Jpn J Clin Oncol; 2020 Mar; 50(3):325-332. PubMed ID: 32039443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH-mutated gliomas revealed by mass spectrometry imaging.
    Kampa JM; Kellner U; Marsching C; Ramallo Guevara C; Knappe UJ; Sahin M; Giampà M; Niehaus K; Bednarz H
    Neuropathology; 2020 Dec; 40(6):546-558. PubMed ID: 32662157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.
    Tuna G; Dal-Bekar NE; Akay A; Rükşen M; İşlekel S; İşlekel GH
    J Neuropathol Exp Neurol; 2022 Jun; 81(7):502-510. PubMed ID: 35582888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
    Lai A; Kharbanda S; Pope WB; Tran A; Solis OE; Peale F; Forrest WF; Pujara K; Carrillo JA; Pandita A; Ellingson BM; Bowers CW; Soriano RH; Schmidt NO; Mohan S; Yong WH; Seshagiri S; Modrusan Z; Jiang Z; Aldape KD; Mischel PS; Liau LM; Escovedo CJ; Chen W; Nghiemphu PL; James CD; Prados MD; Westphal M; Lamszus K; Cloughesy T; Phillips HS
    J Clin Oncol; 2011 Dec; 29(34):4482-90. PubMed ID: 22025148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients.
    Ferrer VP
    Cancer Genet; 2023 Jan; 270-271():22-30. PubMed ID: 36436416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
    Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
    J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.